SubsidieMeestersClinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
Projectdetails
Introduction
Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today counts only with a few (ineffective) approved therapies.
Discovery and Development
Using a machine learning algorithm, we have discovered a correlation between a small molecule and an unexplored target in GBM. We have developed a hydrogel-based formulation of the molecule with great safety and efficacy in vivo.
Efficacy Results
Our formulation showed:
- 40% long-term survival in a GBM rat model
- Complete tumour eradication after a single dose treatment
Treatment Overview
NANO-PL is a one-time treatment, applied locally during surgery, which is effective even in GBM cells that are resistant to the standard of care or those involved in recurrence.
Synergistic Effects
NANO-PL also showed a synergistic efficacy with temozolomide, the standard-of-care.
Future Directions
The EIC will enable the clinical validation of NANO-PL, completely unlocking the GBM treatment.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.800.691 |
Tijdlijn
| Startdatum | 1-11-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- TARGTEX SApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC POC | € 150.000 | 2022 | Details |
Novel therapeutic platform for aggressive lymphoma: NanoLymphomaNanoLymphoma aims to develop a novel therapeutic platform using nanofilaments to cluster multiple lymphoma targets, enhancing tumor cell death and providing a promising treatment for aggressive B-cell lymphoma. | ERC POC | € 150.000 | 2023 | Details |
Preclinical in vivo validation of a glioblastoma neuro snooper electrical deviceThis project aims to develop and validate the 'GBM Neuro Snooper' device to improve understanding and treatment of glioblastoma by assessing brain electrophysiology post-tumor resection. | ERC POC | € 150.000 | 2023 | Details |
Trapping and Killing GlioblastomaTrapKill aims to enhance glioblastoma treatment by using a functionalized hydrogel to disrupt DNA repair mechanisms and improve the efficacy of chemo-radiotherapy. | ERC STG | € 1.499.938 | 2025 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Novel therapeutic platform for aggressive lymphoma: NanoLymphoma
NanoLymphoma aims to develop a novel therapeutic platform using nanofilaments to cluster multiple lymphoma targets, enhancing tumor cell death and providing a promising treatment for aggressive B-cell lymphoma.
Preclinical in vivo validation of a glioblastoma neuro snooper electrical device
This project aims to develop and validate the 'GBM Neuro Snooper' device to improve understanding and treatment of glioblastoma by assessing brain electrophysiology post-tumor resection.
Trapping and Killing Glioblastoma
TrapKill aims to enhance glioblastoma treatment by using a functionalized hydrogel to disrupt DNA repair mechanisms and improve the efficacy of chemo-radiotherapy.